Gilead to buy CymaBay Therapeutics for $32.50 per share in cash deal worth $4.3 billion
MLex Summary: Gilead Sciences has agreed to buy CymaBay Therapeutics for $32.50 per share in cash. The deal is worth $4.3 billion and will add CymaBay's investigational treatment of primary biliary cholangitis...To view the full article, register now.
Already a subscriber? Click here to view full article